Similarly, studies have shown that nickel exposure could significantly decrease the expression of hOGG1 and increase the PARP sensitivity to PARP inhibitors [51], suggesting that nickel-based derivatives could be a potential PARP inhibitor adjuvant therapy to enhance its efficacy during the cancer treatment. This evidence concerns the gene OGG1 and cancer.